Tests EVO756 for preventing migraine in adults
Tests EVO756 against placebo to prevent migraine in adults aged 18 to 64.
Key facts
- Who runs it
- Evommune, Inc.
- Where
- Blacktown and Saint Albans, AustraliaSee the 2 sitesAlso in 3 other countries, 43 sites
- Trial code
- Registry title
- Study of EVO756 in Adults With Migraine
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 330 people, planned
- Started
- 29 Jul 2026
- Expected to end
- Nov 2027
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- EVO756, Dose 1
- EVO756, Dose 2
- Placebo
- Record updated
- 4 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with migraine who have tried preventive migraine treatments that did not work. It tests EVO756 against placebo.
- Age
- 18 to under 65 years (18 to 64 years).
- Sex
- All sexes can join.
- Disease stage
- Migraine with or without aura, as defined by ICHD-3 criteria.
- Earlier treatment
- Must have had no success with earlier preventive migraine treatments. Must not be using a migraine preventive treatment now.
Main reasons for not taking part
- Difficulty telling migraine apart from other headache types
- Other primary headache disorders
- Use of certain medications
- Any clinically significant medical, psychiatric, neurological, cardiovascular or laboratory abnormalities
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Adults aged 18 to <65 years
- Migraine with or without aura, per ICHD-3 criteria
- History of failure with prior preventive migraine treatments
- Not currently using migraine preventive therapy
Who cannot take part
- Use of certain medications
- Difficulty distinguishing migraine from other headache types or presence of other primary headache disorders
- Any clinically significant medical, psychiatric, neurological, cardiovascular, or laboratory abnormalities
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Australia
Also in 3 other countries, 43 sites
- Paratus Clinical Research Western SydneyBlacktown, AustraliaContact: EVO756-MIG001 Research SiteTaking people
- Momentum Clinical Research - Sunshine MelbourneSaint Albans, AustraliaContact: EVO756-MIG001 Research SiteTaking people
About the trial
What the trial wants to find out
This study will evaluate the efficacy and safety of EVO756 against placebo in adults with migraine.
The 3 groups in the trial
- Dose 1Treatment being tested
Orally administered EVO756, Dose 1 (Daily)
Treatment: EVO756, Dose 1
- Dose 2Treatment being tested
Orally administered EVO756, Dose 2 (Daily)
Treatment: EVO756, Dose 2
- PlaceboPlacebo, for comparison
Placebo control (Daily)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Randomized, Double-Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of EVO756 for the Prevention of Migraine in Adults
- Plain-language title
- Tests EVO756 for preventing migraine in adultsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Fit questions
- Built from NCT07616128, who can take part
- Record updated
- 4 November 2026